These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

838 related articles for article (PubMed ID: 32730798)

  • 1. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
    Fleseriu M; Pivonello R; Young J; Hamrahian AH; Molitch ME; Shimizu C; Tanaka T; Shimatsu A; White T; Hilliard A; Tian C; Sauter N; Biller BM; Bertagna X
    Pituitary; 2016 Apr; 19(2):138-48. PubMed ID: 26542280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
    Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
    Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.
    Gadelha M; Snyder PJ; Witek P; Bex M; Belaya Z; Turcu AF; Feelders RA; Heaney AP; Paul M; Pedroncelli AM; Auchus RJ
    Front Endocrinol (Lausanne); 2023; 14():1236465. PubMed ID: 37680892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.
    Fleseriu M; Pivonello R; Elenkova A; Salvatori R; Auchus RJ; Feelders RA; Geer EB; Greenman Y; Witek P; Cohen F; Biller BMK
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):855-865. PubMed ID: 31542384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
    Gadelha M; Bex M; Feelders RA; Heaney AP; Auchus RJ; Gilis-Januszewska A; Witek P; Belaya Z; Yu Y; Liao Z; Ku CHC; Carvalho D; Roughton M; Wojna J; Pedroncelli AM; Snyder PJ
    J Clin Endocrinol Metab; 2022 Jun; 107(7):e2882-e2895. PubMed ID: 35325149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.
    Fleseriu M; Newell-Price J; Pivonello R; Shimatsu A; Auchus RJ; Scaroni C; Belaya Z; Feelders RA; Vila G; Houde G; Walia R; Izquierdo M; Roughton M; Pedroncelli AM; Biller BMK
    Eur J Endocrinol; 2022 Oct; 187(4):531-541. PubMed ID: 35980235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
    Lacroix A; Gu F; Gallardo W; Pivonello R; Yu Y; Witek P; Boscaro M; Salvatori R; Yamada M; Tauchmanova L; Roughton M; Ravichandran S; Petersenn S; Biller BMK; Newell-Price J;
    Lancet Diabetes Endocrinol; 2018 Jan; 6(1):17-26. PubMed ID: 29032078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.
    Bertagna X; Pivonello R; Fleseriu M; Zhang Y; Robinson P; Taylor A; Watson CE; Maldonado M; Hamrahian AH; Boscaro M; Biller BM
    J Clin Endocrinol Metab; 2014 Apr; 99(4):1375-83. PubMed ID: 24423285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.
    Dauvilliers Y; Arnulf I; Foldvary-Schaefer N; Morse AM; Šonka K; Thorpy MJ; Mignot E; Chandler P; Parvataneni R; Black J; Sterkel A; Chen D; Skobieranda F; Bogan RK
    Lancet Neurol; 2022 Jan; 21(1):53-65. PubMed ID: 34942138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.
    Dougherty JA; Desai DS; Herrera JB
    Ann Pharmacother; 2021 Aug; 55(8):1050-1060. PubMed ID: 33143437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).
    Fleseriu M; Biller BMK; Bertherat J; Young J; Hatipoglu B; Arnaldi G; O'Connell P; Izquierdo M; Pedroncelli AM; Pivonello R
    Pituitary; 2022 Dec; 25(6):959-970. PubMed ID: 36219274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
    Perosevic M; Tritos NA
    Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
    Schopohl J; Gu F; Rubens R; Van Gaal L; Bertherat J; Ligueros-Saylan M; Trovato A; Hughes G; Salgado LR; Boscaro M; Pivonello R;
    Pituitary; 2015 Oct; 18(5):604-12. PubMed ID: 25537481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osilodrostat for the treatment of Cushing's disease.
    Rasool S; Skinner BW
    Expert Opin Pharmacother; 2021 Jun; 22(9):1099-1106. PubMed ID: 33703978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
    Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.
    Pivonello R; Fleseriu M; Newell-Price J; Shimatsu A; Feelders RA; Kadioglu P; Tabarin A; Brue TC; Geer EB; Piacentini A; Pedroncelli AM; Biller BMK
    J Endocrinol Invest; 2024 Oct; 47(10):2437-2448. PubMed ID: 38696122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease.
    Fontaine-Sylvestre C; Létourneau-Guillon L; Moumdjian RA; Berthelet F; Lacroix A
    Pituitary; 2021 Apr; 24(2):207-215. PubMed ID: 33074401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
    Plazzi G; Ruoff C; Lecendreux M; Dauvilliers Y; Rosen CL; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
    Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
    Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
    Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.